Monitor for initiation of patient dosing and any early safety or biomarker readouts, which could provide further validation of VY1706's therapeutic potential. The small trial size (18 patients) limits near-term binary risk, but positive data could significantly de-risk the program.
Price Chart
Executive Summary
Voyager Therapeutics announced FDA clearance of its IND application for VY1706, a tau silencing gene therapy for Alzheimer's disease. The company plans a Phase 1 open-label dose-escalation trial in up to 18 patients with early Alzheimer's, with dosing expected to begin in H2 2026. This is a positive regulatory milestone for the pipeline, but the program remains early-stage with no financial data disclosed.
Key Facts
- FDA cleared IND for VY1706, a tau silencing gene therapy for Alzheimer's disease
- Phase 1 trial is open-label, dose-escalation, enrolling up to 18 patients with early Alzheimer's and tau pathology confirmed by PET
- Dosing expected to begin in the second half of 2026
- Primary endpoint is safety and tolerability; secondary endpoints include CSF tau biomarkers and tau PET imaging
- Highest dose not exceeding 5 x 10^13 vector genomes per kilogram
Financial Impact
No financial figures disclosed; preclinical-stage catalyst with no immediate revenue impact
Risk Factors
- Clinical trial failure due to safety or lack of efficacy
- Slow enrollment or delays in trial initiation
- Competition from other Alzheimer's therapies targeting tau or amyloid
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-068591 |
| Document: 0001104659-26-068591-index-headers.html | 0001104659-26-068591 |
| Document: 0001104659-26-068591-index.html | 0001104659-26-068591 |
| Document: 0001104659-26-068591.txt | 0001104659-26-068591 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 8-K | $2.02 | awaiting T+60 | — | $1.79 (−11.39%) |
Jul 13, 2026 15w ago | 8-K | $3.24 $2.46 | ▼ −24.07% | ▼ −28.07% | $1.79 (−44.75%) |
Jun 1, 2026 21w ago | 8-K | $3.79 $3.48 | ▼ −8.18% | ▼ −9.41% | $1.79 (−52.77%) |
May 13, 2026 23w ago | Press Release | $4.15 $3.27 | ▼ −21.20% | ▼ −25.64% | $1.79 (−56.87%) |
May 7, 2026 24w ago | Press Release | $4.05 $3.13 | ▼ −22.84% | ▼ −27.68% | $1.79 (−55.80%) |
Apr 27, 2026 26w ago | Press Release | $3.77 $3.09 | ▼ −18.04% | ▼ −22.03% | $1.79 (−52.52%) |
Apr 21, 2026 26w ago | 8-K | $4.14 $3.17 | ▼ −23.43% | ▼ −28.21% | $1.79 (−56.76%) |
Feb 24, 2026 35w ago | Insider Cluster | $3.78 $3.48 | ▲ +7.94% | ▲ +14.68% | $1.79 (+52.65%) |
Feb 24, 2026 35w ago | Insider Cluster | $3.78 $3.48 | ▲ +7.94% | ▲ +14.68% | $1.79 (+52.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers